{
  "label": "clinical_signal_03_ep_028",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:7fd745e408062546662516d75e53d7bb09998d91ef133d3c4add3a6121a4bb91",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:45.897561",
  "content": "## 2024-09-09 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 220\n- Active: 200\n- Screen Failures Cumulative: 48\n- Withdrawals Cumulative: 20\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 15\n- Site 10 Active: 15\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 51\n- ALT (U/L) Mean: 166.2\n- ALT (U/L) Median: 164.2\n- AST (U/L) Mean: 115.1\n- AST (U/L) Median: 113.9\n- Bilirubin (mg/dL) Mean: 2.84\n- Bilirubin (mg/dL) Median: 2.8\n- ALP (U/L) Mean: 67.4\n- ALP (U/L) Median: 79.6\n- Creatinine (mg/dL) Mean: 0.91\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 12.2\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 5.6\n- WBC (K) Median: 7.3\n- Platelets (K) Mean: 242\n- Platelets (K) Median: 246\n\n#### Non-Statin Subgroup\n- N: 123\n- ALT (U/L) Mean: 29.1\n- ALT (U/L) Median: 28.5\n- AST (U/L) Mean: 21.3\n- AST (U/L) Median: 20.1\n- Bilirubin (mg/dL) Mean: 0.58\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 57.4\n- ALP (U/L) Median: 49.0\n- Creatinine (mg/dL) Mean: 1.03\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 12.9\n- BUN (mg/dL) Median: 13.0\n- WBC (K) Mean: 7.8\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 256\n- Platelets (K) Median: 213\n\n### Adverse Events\n- AE ID: AE-0115, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0116, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0117, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0118, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0119, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 31\n- ACE Inhibitor Count: 28\n- Metformin Count: 22\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-059, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n- PD ID: PD-060, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_12\n\n### Investigator Notes\n- EDC data entry backlog cleared, queries resolved\n- Study drug accountability reconciled, no discrepancies\n- Regulatory binder audit: all documents current\n- 10 of 12 sites have implemented protocol amendment; 2 sites pending local IRB\n\n### Events\n- Medical monitor weekly call completed\n- Bioanalytical lab shipment tracking confirmed for 4 samples\n- IVRS system update deployed, randomization unaffected\n- Site implementation tracking: 10/12 sites active on amended protocol\n\n### Notes\n- Week 28: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_028",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-09-09T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}